Loading…
Propanc Biopharma, Inc. is projected to rise to $1.67 by 2027, a +3% move from its current price of $1.62. PPCB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.47 | $1.62 | $1.78 | +0.11% |
| May 30 | $1.42 | $1.62 | $1.86 | +0.22% |
| May 31 | $1.38 | $1.63 | $1.92 | +0.34% |
| Jun 1 | $1.35 | $1.63 | $1.97 | +0.45% |
| Jun 2 | $1.32 | $1.63 | $2.01 | +0.56% |
| Jun 3 | $1.29 | $1.63 | $2.06 | +0.67% |
| Jun 4 | $1.27 | $1.63 | $2.10 | +0.79% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.27 | $1.63 | $2.10 | +0.79% |
| Week 2 | $1.15 | $1.65 | $2.35 | +1.58% |
| Week 3 | $1.07 | $1.66 | $2.56 | +2.38% |
| Week 4 | $1.01 | $1.67 | $2.76 | +3.19% |
| Week 5 | $0.96 | $1.68 | $2.96 | +4.00% |
| Week 6 | $0.917 | $1.70 | $3.14 | +4.82% |
| Week 7 | $0.8797 | $1.71 | $3.33 | +5.65% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Propanc Biopharma, Inc. is a development-stage biopharmaceutical healthcare company focused on cancer treatments in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention, which has completed pre-clinical studies.
The company has research and collaboration agreements with the University of Jaén to undertakes the research activities for the POP1 Program and with the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc.
in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.
Propanc Biopharma, Inc. (PPCB) currently trades at $1.62 with a market capitalization of $3.69M and ranks 5339 by market cap.
The price outlook according to the provided forecasts shows upside potential over time, with the 2026 average price at $1.62 and the 2030 average at $2.49. The long-run path includes a 2050 average price of $6.73 and a maximum of $15.48, with a 2050 ROI of 315.4% and a bullish sentiment for the later years.
The forecast also shows notable higher-year max values such as $4.35 in 2030 and $15.48 in 2050, signaling meaningful upside from current levels despite a near-term mixed view.
A major floor 61.0% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 91.5% above — a clean break opens room to run.
A major ceiling 501.9% above — clearing it would confirm fresh momentum.
Key PPCB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PPCB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.72 | Sell | $1.74 | Sell |
| MA 10 | $1.85 | Sell | $1.87 | Sell |
| MA 20 | $2.15 | Sell | $2.09 | Sell |
| MA 50 | $2.53 | Sell | $3.12 | Sell |
| MA 100 | $4.57 | Sell | $9.05 | Sell |
| MA 200 | $25.71 | Sell | $25.47 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 31.86 | Neutral |
| Stoch RSI (14) | 37.08 | Neutral |
| CCI (20) | -112.11 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -26.86 | Sell |
| Bollinger %B (20,2) | 0.11 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.41 | Sell |
| Awesome (5,34) | -0.66 | Sell |
| Ultimate (7,14,28) | 38.91 | Neutral |
| Momentum (10) | -0.64 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 1.65 | Sell |
| ADX (14) | 28.10 | Sell |
| ATR (14) | 0.13 | Info |
The 30-day technical picture is bearish, with RSI14 at 30. The stock is trading below the 50-day simple moving average of $2.53 and well below the 200-day simple moving average of $25.71.
Support is listed at $1.62 and resistance at $3.10, with the 30-day price range extending from $0.8657 to $3.03. The overall volatility is high, as suggested by the annualized volatility of 200%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.62 | $1.62 | $2.19 | 0% | Neutral | |
| $1.20 | $1.67 | $2.52 | +3% | Neutral | |
| $1.61 | $2.38 | $3.80 | +47% | Bullish | |
| $1.56 | $2.43 | $4.07 | +50% | Bullish | |
| $1.53 | $2.49 | $4.35 | +54% | Bullish | |
| $1.55 | $2.63 | $4.75 | +63% | Bullish | |
| $1.20 | $2.12 | $3.94 | +31% | Bullish | |
| $1.17 | $2.16 | $4.12 | +33% | Bullish | |
| $1.15 | $2.21 | $4.33 | +37% | Bullish | |
| $1.30 | $2.58 | $5.17 | +59% | Bullish | |
| $1.30 | $2.88 | $6.33 | +78% | Bullish | |
| $3.03 | $6.73 | $15.48 | +315% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.62 | $1.62 | $1.93 | +0.00% |
| June 2026 | $1.47 | $1.76 | $2.18 | +8.48% |
| July 2026 | $1.47 | $1.79 | $2.29 | +2.10% |
| August 2026 | $1.34 | $1.65 | $2.15 | -7.95% |
| September 2026 | $1.31 | $1.64 | $2.17 | -0.61% |
| October 2026 | $1.38 | $1.74 | $2.33 | +5.93% |
| November 2026 | $1.31 | $1.67 | $2.27 | -3.69% |
| December 2026 | $1.24 | $1.60 | $2.19 | -4.63% |
Click any year to see its month-by-month PPCB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, PPCB is projected to trade between $1.62 and $2.19, averaging $1.62 — a potential gain of 0% from today's $1.62. Price action looks broadly range-bound.
Propanc Biopharma, Inc.'s 2027 outlook centres on $1.67, within a $1.20 to $2.52 range. That is up +3% on the projected 2026 average. That marks a +3% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, PPCB could reach as high as $3.80, with a base case around $2.38 and support toward $1.61 — roughly +47% from $1.62. Momentum favours further upside here.
Expect PPCB to range from $1.56 to $4.07 through 2029. The $2.43 average target implies a +50% move from current prices. That is up +2% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The PPCB price prediction for 2030 points to an average of $2.49 (low $1.53, high $4.35) — a potential gain of +54% on today's $1.62. Momentum favours further upside here.
In 2031, PPCB is projected to trade between $1.55 and $4.75, averaging $2.63 — a potential gain of +63% from today's $1.62. That is up +6% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Propanc Biopharma, Inc.'s 2032 outlook centres on $2.12, within a $1.20 to $3.94 range. That is -19% versus the projected 2031 average. That marks a +31% change versus current levels. Momentum favours further upside here.
By 2033, PPCB could reach as high as $4.12, with a base case around $2.16 and support toward $1.17 — roughly +33% from $1.62. Buyers look set to stay in control over this stretch.
Expect PPCB to range from $1.15 to $4.33 through 2034. The $2.21 average target implies a +37% move from current prices. That is up +3% on the projected 2033 average. Momentum favours further upside here.
The PPCB price prediction for 2035 points to an average of $2.58 (low $1.30, high $5.17) — a potential gain of +59% on today's $1.62. Buyers look set to stay in control over this stretch.
In 2040, PPCB is projected to trade between $1.30 and $6.33, averaging $2.88 — a potential gain of +78% from today's $1.62. That is up +11% on the projected 2035 average. Momentum favours further upside here.
Propanc Biopharma, Inc.'s 2050 outlook centres on $6.73, within a $3.03 to $15.48 range. That is up +134% on the projected 2040 average. That marks a +315% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in PPCB today (≈ 617.283951 PPCB) could be worth
$4,153.99
+$3,153.99 (+315%) by 2050 · US Dollar
Based on the average projected PPCB price of $6.73 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PPCBwould be worth at today's price.
$1,000 invested in PPCB on May 27, 2025 (≈ 12.698413 PPCB) would be worth
$20.57
-$979.43 (-97.9%) today · 0.02× · US Dollar
Based on a PPCB entry price of $78.75 vs. today's $1.62.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.76 | $920.45 | -8.0% |
| 1 month ago | $2.59 | $626.09 | -37.4% |
| 3 months ago | $4.88 | $331.97 | -66.8% |
| 6 months ago | $22.34 | $72.52 | -92.7% |
| 1 year ago | $78.75 | $20.57 | -97.9% |
| All time (5.0y) ago | $3,950 | $0.41 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PPCB forecast.
Our base-case forecast reaches $3.20 around 2050.
Implied market cap at $3.20: $7.29M
2026 forecast shows a flat start with min $1.62, avg $1.62, max $2.19 and ROI 0%, reflecting a NEUTRAL sentiment.
2027 projects a modest uptick to min $1.20, avg $1.67, max $2.52 with ROI 3.3% and a NEUTRAL stance.
2028 moves higher to min $1.61, avg $2.38, max $3.80, delivering a 46.7% ROI and a BULLISH sentiment.
2030 advances to min $1.53, avg $2.49, max $4.35 with a 54% ROI and a BULLISH view. By 2031, the forecast shows min $1.55, avg $2.63, max $4.75 and ROI 62.6% (BULLISH), continuing a bullish trajectory through 2035 (min $1.30, avg $2.58, max $5.17, ROI 59.5%). The longer horizon strengthens further in 2040 (min $1.30, avg $2.88, max $6.33, ROI 77.7%, BULLISH) and 2050 (min $3.03, avg $6.73, max $15.48, ROI 315.4%, BULLISH).
The forecast suggests rising upside across the period, with higher average prices and substantial ROI in the distant horizon, alongside elevated volatility.
Tap a question to reveal the answer.
Avg $2.49, min $1.53, max $4.35; ROI 54%; sentiment BULLISH.
The forecasts show a bullish path in later years, with 2050 avg $6.73 and ROI 315.4%; however, near-term signals are mixed and volatility is high (annualized volatility 200%). In 2026 the avg is $1.62 with ROI 0% and NEUTRAL sentiment.
Yes, the forecast shows a max of $5.17 in 2035, indicating a potential to reach around $5 in that year.
Avg $6.73, min $3.03, max $15.48; ROI 315.4%; sentiment BULLISH.
Propanc Biopharma, Inc. Community Discussion
0Share your Propanc Biopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.